Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists
- PMID: 18242983
- DOI: 10.1016/j.bmcl.2008.01.024
Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists
Abstract
Comprehensive SAR studies were undertaken in the 3,4-diaminocyclobut-3-ene-1,2-dione class of CXCR2/CXCR1 receptor antagonists to explore the role of the heterocycle on chemokine receptor binding affinities, functional activity, as well as oral exposure in rat. The nature of the heterocycle as well as the requisite substitution pattern around the heterocycle was shown to have a dramatic effect on the overall biological profile of this class of compounds. The furyl class, particularly the 4-halo adducts, was found to possess superior binding affinities for both the CXCR2 and CXCR1 receptors, functional activity, as well as oral exposure in rat versus other heterocyclic derivatives.
Similar articles
-
Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.Bioorg Med Chem Lett. 2009 Aug 1;19(15):4446-9. doi: 10.1016/j.bmcl.2009.05.049. Epub 2009 May 18. Bioorg Med Chem Lett. 2009. PMID: 19525110
-
Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.Bioorg Med Chem Lett. 2006 Aug 1;16(15):4107-10. doi: 10.1016/j.bmcl.2006.04.082. Epub 2006 May 11. Bioorg Med Chem Lett. 2006. PMID: 16697193
-
3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.Bioorg Med Chem Lett. 2008 Jan 1;18(1):228-31. doi: 10.1016/j.bmcl.2007.10.094. Epub 2007 Oct 30. Bioorg Med Chem Lett. 2008. PMID: 18006311
-
Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.Pulm Pharmacol Ther. 2015 Oct;34:37-45. doi: 10.1016/j.pupt.2015.08.002. Epub 2015 Aug 10. Pulm Pharmacol Ther. 2015. PMID: 26271598 Review.
-
ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.Pharmacol Ther. 2006 Oct;112(1):139-49. doi: 10.1016/j.pharmthera.2006.04.002. Epub 2006 May 23. Pharmacol Ther. 2006. PMID: 16720046 Review.
Cited by
-
QSAR models for CXCR2 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the PLS linear regression method and design of the new compounds using in silico virtual screening.Molecules. 2011 Feb 25;16(3):1928-55. doi: 10.3390/molecules16031928. Molecules. 2011. PMID: 21358586 Free PMC article.
-
Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.Theranostics. 2017 Apr 7;7(6):1543-1588. doi: 10.7150/thno.15625. eCollection 2017. Theranostics. 2017. PMID: 28529637 Free PMC article. Review.
-
Design, Synthesis, and Application of Fluorescent Ligands Targeting the Intracellular Allosteric Binding Site of the CXC Chemokine Receptor 2.J Med Chem. 2023 Sep 28;66(18):12911-12930. doi: 10.1021/acs.jmedchem.3c00849. Epub 2023 Jul 31. J Med Chem. 2023. PMID: 37523859 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous